Scott Morton backs Biden administration to tackle exclusionary conduct in drugs markets

Challenging pharmaceutical companies’ exclusionary conduct is a “low-hanging fruit” that could help the Biden administration lower the cost of drugs in the US, a former Department of Justice official has said.


Get unlimited access to all Global Competition Review content